Abstract

Purpose Yttrium-90 radioembolization (RE) treatment of hepatocellular carcinoma (HCC) may be performed with either resin or glass microspheres. Differences include specific activity, microsphere size and density, embolic effect, and dose calculation. We retrospectively reviewed the differences in outcome between patients treated with glass microspheres and patients treated with resin microspheres prior to availability of glass microspheres at two centers. Materials and Methods All patients with HCC treated with either resin or glass microspheres at two collaborating centers were reviewed, including patients treated with glass microspheres at one institution. Dose calculation was based on body surface area (resin) or liver weight partition model (glass). Radiographic response was measured at 3 and 6 months according to mRECIST criteria. Laboratory and clinical follow-up was performed at 2, 4, 8 and 12 weeks. Parameters of toxicity and efficacy were compared. Results Seventy patients were treated (54 M, 16 F; median age 61; 18 resin, 52 glass microspheres). Baseline laboratory, tumor, and clinical parameters were comparable between groups, with the exception of a higher ECOG-score in the glass microsphere patients (p = 0.001). Patients treated with resin microspheres received less activity (1.41 versus 3.76 GBq; p Conclusion Higher dose glass microspheres may have a subtle response and survival advantage for yttrium-90 RE of HCC.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.